UNSPSC 51342402: Saquinavir

This classification denotes a protease inhibitor with the molecular formula C38H50N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3JE09KZ2F, chemically known as butanediamide, n1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3alpha,4aalpha,8aalpha))- but generally known as saquinavir, which bears US NIH Compound Identifier 60787.

UNSPSC 51342402 Saquinavir, a Commodity code, nominally covers antiretroviral pharmaceutical products; however, the recent state and local opportunities tagged under this code do not align with saquinavir procurement. Instead, the tagged records document pharmaceutical warehouse supply agreements and harm-reduction product acquisitions (naloxone and drug deactivation systems) that fall outside the saquinavir scope. State and local health departments and county public health agencies are using this code to consolidate competitive pharmaceutical purchases through cooperative purchasing vehicles and fixed-term supply contracts, but the products actually being procured—doxycycline, ciprofloxacin, naloxone, and drug deactivation equipment—reflect broader public health and emergency preparedness needs rather than HIV treatment regimens. The code appears to function as a catch-all for state and local pharmaceutical procurement rather than a narrow category tracking a single active pharmaceutical ingredient.

Activity under this code spans Illinois (Department of Public Health) and Florida (Seminole County), with both leveraging existing cooperative purchasing agreements and Invitation for Bid processes to manage volume commitments and pricing. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC on August 28, 2026, under the MMCAP Infuse consortium for a 12-month initial term with renewal options through year 3; Seminole County, Florida released an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a two-year initial contract term plus one-year renewal option. Both procurements require electronic submission and include standard compliance certifications (drug-free workplace, E-Verify). The code shows limited recent activity and a material mismatch between its nominal scope and the products actually being acquired.